Hyperpituitarism disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HYP070 MIFTS: 42	Hyperpituitarism Categories: Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Hyperpituitarism

MalaCards integrated aliases for Hyperpituitarism:

Name: Hyperpituitarism ¹² ⁴⁵ ¹⁵ ¹⁷ ⁷⁴

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:2444

MeSH ⁴⁵ D006964

SNOMED-CT ⁶⁹ 10649000

EFO ¹⁷ EFO_1000973

UMLS ⁷⁴ C0020506

Sources

Summaries for Hyperpituitarism

MalaCards based summary : Hyperpituitarism is related to hyperthyroidism and hypopituitarism. An important gene associated with Hyperpituitarism is IGF1 (Insulin Like Growth Factor 1), and among its related pathways/superpathways are TGF-Beta Pathway and PI3K-Akt signaling pathway. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : ⁷⁷ Hyperpituitarism is a condition due to the primary hypersecretion of pituitary hormones; it typically... more...

Sources

Related Diseases for Hyperpituitarism

Diseases related to Hyperpituitarism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)

#	Related Disease	Score	Top Affiliating Genes
1	hyperthyroidism	29.7	GH1 INS PRL SST TRH
2	hypopituitarism	29.2	GH1 GHRH IGF1 INS POMC PRL
3	galactorrhea	10.4	IGF1 PRL
4	glucagonoma	10.3	GHRH SST
5	prolactin producing pituitary tumor	10.3	PRL SST
6	mammographic density	10.3	IGF1 PRL
7	pancreatic cholera	10.3	GHRH SST
8	bronchus adenoma	10.3	POMC SST
9	bronchial adenomas/carcinoids childhood	10.3	POMC SST
10	generalized resistance to thyroid hormone	10.3	PRL TRH
11	zollinger-ellison syndrome	10.3	GHRH SST
12	spinocerebellar degeneration	10.3	PRL SST
13	fasting hypoglycemia	10.3	IGF1 POMC
14	central precocious puberty	10.3	GH1 IGF1
15	marasmus	10.3	GH1 IGF1
16	fibrous dysplasia/mccune-albright syndrome	10.3	GH1 PRL
17	secondary adrenal insufficiency	10.3	IGF1 INS
18	acth-secreting pituitary adenoma	10.3	POMC PRL
19	suprasellar meningioma	10.3	POMC TRH
20	pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities	10.3	IGF1 INS
21	cone-rod dystrophy 12	10.3	GH1 IGF1
22	duodenal somatostatinoma	10.2	INS SST
23	somatostatinoma	10.2	INS SST
24	postgastrectomy syndrome	10.2	INS SST
25	abducens nerve disease	10.2	POMC PRL
26	noma	10.2	INS POMC
27	insulinomatosis and diabetes mellitus	10.2	INS SST
28	donohue syndrome	10.2	IGF1 INS
29	lymphocytic hypophysitis	10.2	GH1 POMC
30	diabetes insipidus, neurohypophyseal	10.2	POMC PRL
31	carcinoid syndrome	10.2	GHRH IGF1 SST
32	fibromyalgia	10.2	IGF1 PRL
33	dumping syndrome	10.2	INS SST
34	hypoadrenalism	10.2	GH1 POMC
35	traumatic brain injury	10.2	GH1 IGF1
36	ectopic cushing syndrome	10.2	POMC SST
37	graves' disease	10.2
38	scleredema adultorum	10.2	INS POMC
39	functional gastric disease	10.2	INS SST
40	acromesomelic dysplasia, maroteaux type	10.2	GHR IGF1
41	acidophil adenoma	10.2	IGF1 POMC SST
42	pancreatic cystadenoma	10.2	INS SST
43	tetrahydrobiopterin deficiency	10.2	GH1 PRL
44	graves disease 1	10.2	INS TRH
45	fetal macrosomia	10.2	IGF1 INS
46	gastrinoma	10.2	INS SST
47	premenstrual tension	10.2	POMC PRL
48	mucinoses	10.2	INS POMC
49	growth hormone deficiency	10.1	GH1 GHRH IGF1
50	chiasmal syndrome	10.1	POMC PRL SST

Graphical network of the top 20 diseases related to Hyperpituitarism:

Sources

Symptoms & Phenotypes for Hyperpituitarism

GenomeRNAi Phenotypes related to Hyperpituitarism according to GeneCards Suite gene sharing:

²⁷ (show all 24)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-101	9.8	GH1 POMC SSTR2
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-102	9.8	POMC
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-12	9.8	GH1
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-127	9.8	POMC
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-130	9.8	GH1 SSTR2
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-133	9.8	SSTR2
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-135	9.8	GH1
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-137	9.8	SSTR2
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-138	9.8	SSTR2
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	9.8	GH1
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-152	9.8	SSTR2
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-157	9.8	SSTR2
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	9.8	GH1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-164	9.8	SSTR2
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	9.8	GH1 SSTR2
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-29	9.8	POMC
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-32	9.8	POMC
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-52	9.8	SSTR2
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-54	9.8	GH1 SSTR2
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-56	9.8	SSTR2
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-67	9.8	SSTR2
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-88	9.8	POMC
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-9	9.8	POMC SSTR2
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-96	9.8	GH1

MGI Mouse Phenotypes related to Hyperpituitarism:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland	MP:0005379	9.97	AIP GHR GHRH IGF1 INS POMC
2	homeostasis/metabolism	MP:0005376	9.96	AIP GHR GHRH IGF1 INS POMC
3	growth/size/body region	MP:0005378	9.92	AIP GHR GHRH IGF1 INS POMC
4	integument	MP:0010771	9.63	AIP GHR IGF1 INS POMC PRL
5	liver/biliary system	MP:0005370	9.43	AIP GHR GHRH INS POMC PRL
6	nervous system	MP:0003631	9.28	GHR GHRH IGF1 INS POMC PRL

Sources

Drugs & Therapeutics for Hyperpituitarism

Drugs for Hyperpituitarism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dopamine

Approved

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

62-31-7, 51-61-6

681

Risperidone

Approved, Investigational

Phase 4,Phase 3,Not Applicable

106266-06-2

5073

Aripiprazole

Approved, Investigational

Phase 4,Not Applicable

129722-12-9

60795

lanreotide

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

108736-35-2

Octreotide

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

83150-76-9

6400441 383414

Somatostatin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

38916-34-6, 51110-01-1

53481605

Pasireotide

Approved

Phase 4,Phase 3,Phase 2,Phase 1

396091-73-9

9941444

Mecasermin

Approved, Investigational

Phase 4,Phase 3,Not Applicable

68562-41-4

Quinagolide

Approved, Investigational

Phase 4

87056-78-8, 97805-50-0

105105

Cabergoline

Approved

Phase 4,Phase 3,Phase 2

81409-90-7

54746

Liraglutide

Approved

Phase 4

204656-20-2

44147092

Metformin

Approved

Phase 4

657-24-9

14219 4091

Zinc

Approved, Investigational

Phase 4

7440-66-6

32051

Estradiol

Approved, Investigational, Vet_approved

Phase 4

50-28-2

5757

Polyestradiol phosphate

Approved

Phase 4

28014-46-2

Lactitol

Investigational

Phase 4,Phase 3,Phase 1

585-86-4, 585-88-6

493591

Dopamine Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Antidepressive Agents

Phase 4,Not Applicable

Central Nervous System Depressants

Phase 4,Phase 3,Phase 2,Not Applicable

Dopamine agonists

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Dopamine D2 Receptor Antagonists

Phase 4,Not Applicable

Serotonin 5-HT1 Receptor Agonists

Phase 4,Not Applicable

Serotonin Receptor Agonists

Phase 4,Not Applicable

Psychotropic Drugs

Phase 4,Phase 3,Phase 2,Not Applicable

Neurotransmitter Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Serotonin Agents

Phase 4,Phase 3,Not Applicable

Serotonin Antagonists

Phase 4,Phase 3,Not Applicable

Antipsychotic Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Serotonin 5-HT2 Receptor Antagonists

Phase 4,Not Applicable

Paliperidone Palmitate

Phase 4

Dopamine Antagonists

Phase 4,Phase 3,Not Applicable

Tranquilizing Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Mitogens

Phase 4,Phase 3,Phase 2,Not Applicable

Angiopeptin

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Hormones

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Insulin, Globin Zinc

Phase 4,Phase 3,Phase 2,Not Applicable

Antineoplastic Agents, Hormonal

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

insulin

Phase 4,Phase 3,Phase 2,Not Applicable

Gastrointestinal Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antiparkinson Agents

Phase 4,Phase 3,Phase 1,Phase 2

Incretins

Phase 4,Not Applicable

Liver Extracts

Phase 4

Cardiotonic Agents

Phase 4,Phase 1,Phase 2

Protective Agents

Phase 4,Phase 1,Phase 2

Autonomic Agents

Phase 4,Phase 2,Phase 1

Sympathomimetics

Phase 4,Phase 1,Phase 2

Peripheral Nervous System Agents

Phase 4,Phase 2,Phase 1

Hypoglycemic Agents

Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 214)

#	Name	Status	NCT ID	Phase	Drugs
1	A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders	Unknown status	NCT01742390	Phase 4	Aripiprazole;risperidone or paliperidone
2	Pasireotide LAR and Pegvisomant Study in Acromegaly	Unknown status	NCT02668172	Phase 4	Pasireotide LAR 60 mg;Pegvisomant
3	Effects of Sandostatin LAR® in Acromegaly	Unknown status	NCT01424241	Phase 4	Sandostatin LAR
4	Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia	Unknown status	NCT00541554	Phase 4	Abilify (aripiprazole)
5	Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant	Unknown status	NCT00552851	Phase 4	pegvisomant
6	Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment	Completed	NCT03080181	Phase 4	Pasireotide 0.6 MG/ML
7	Aripiprazole and Prolactin Study	Completed	NCT01085383	Phase 4	Aripiprazole
8	Endometriosis Patients Undergoing Quinagolide Treatment	Completed	NCT00625950	Phase 4
9	Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target	Completed	NCT01618513	Phase 4	Sandostatin® LAR
10	Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients	Completed	NCT01278342	Phase 4	Sandostatin LAR;pegvisomant;cabergoline
11	Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly	Completed	NCT02060383	Phase 4	Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
12	Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects	Completed	NCT00701363	Phase 4	Lanreotide Autogel 120 mg
13	Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients	Completed	NCT00642720	Phase 4	Pegvisomant
14	Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly	Completed	NCT00627796	Phase 4	Lanreotide-Autogel 120 mg
15	Acute Application of Pegvisomant and Octreotide in Acromegaly	Completed	NCT00595140	Phase 4	pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
16	Ultrasound Guided Octreotide LAR Injection in Acromegaly	Completed	NCT00552071	Phase 4	Octreotide LAR 30 MG Injection
17	Preoperative Octreotide Treatment of Acromegaly	Completed	NCT00521300	Phase 4	Octreotide
18	Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly	Completed	NCT00461149	Phase 4	Octreotide-LAR
19	Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly	Completed	NCT00376064	Phase 4	Octreotide acetate and cabergoline/Octrotide and Somavert
20	Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR	Completed	NCT00216398	Phase 4	Lanreotide (Autogel formulation)
21	Octreotide Efficacy and Safety in First-line Acromegalic Patients	Completed	NCT00171886	Phase 4	Octreotide
22	Canadian Pegvisomant Compassionate Study In Acromegalic Patients	Completed	NCT00151437	Phase 4	Pegvisomant treatment
23	Somatuline Autogel: Acromegaly Self/Partner Injection Study	Completed	NCT00149188	Phase 4	Lanreotide (Autogel formulation)
24	Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction	Completed	NCT00145405	Phase 4	Lanreotide Autogel and Octreotide LAR
25	A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly	Completed	NCT00068042	Phase 4	Pegvisomant;Sandostatin LAR
26	Pegvisomant And Sandostatin LAR Combination Study	Completed	NCT00068029	Phase 4	Pegvisomant/ Sandostatin LAR;Sandostatin LAR;Pegvisomant
27	Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues	Recruiting	NCT02427295	Phase 4	Sandostatin (Octreotide Acetate)
28	Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.	Recruiting	NCT01794793	Phase 4	Pasireotide
29	A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.	Terminated	NCT01861717	Phase 4	lanreotide
30	The Luveris In Vitro Fertilization Trial	Terminated	NCT00889512	Phase 4	Luveris fixed dose;Luveris increasing dose
31	Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas	Terminated	NCT00242541	Phase 4	Octreotide acetate
32	Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine	Unknown status	NCT00315081	Phase 3	Bromocriptin
33	Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease	Completed	NCT01374906	Phase 3	pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
34	An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.	Completed	NCT01582061	Phase 3	Pasireotide sub-cutaneous
35	Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia	Completed	NCT00799383	Phase 3	Calcium and Vitamin D
36	Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease	Completed	NCT00434148	Phase 3	Pasireotide
37	Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly	Completed	NCT02493517	Phase 3	Lanreotide Autogel®;Lanreotide Acetate
38	Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues	Completed	NCT02354508	Phase 3	Pasireotide LAR
39	Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly	Completed	NCT01412424	Phase 3	Octreotide capsules
40	Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly	Completed	NCT01137682	Phase 3	Pasireotide;octreotide LAR 30mg;lanreotide ATG 120mg
41	Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma	Completed	NCT00690898	Phase 3	Lanreotide autogel 120 mg
42	Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients	Completed	NCT00635765	Phase 3	C2L-OCT-01 PR 30 mg
43	Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients	Completed	NCT00616551	Phase 3	C2L-OCT-01 PR, 30 mg;Octreotide acetate prolonged release, 30 mg
44	Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly	Completed	NCT00600886	Phase 3	Pasireotide;Octreotide
45	Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly	Completed	NCT00499993	Phase 3	lanreotide (Autogel formulation), duration of treatment 46-48 weeks
46	Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel	Completed	NCT00447499	Phase 3	Somatuline Autogel (lanreotide acetate)
47	Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly	Completed	NCT00444873	Phase 3	lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
48	Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome	Completed	NCT01371565	Phase 3	Mifepristone
49	Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients	Completed	NCT00383708	Phase 3	lanreotide (Autogel formulation);Pegvisomant
50	Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly	Completed	NCT00372697	Phase 3	Octreotide acetate 30 mg suspension

Search NIH Clinical Center for Hyperpituitarism

Cochrane evidence based reviews: hyperpituitarism

Sources

Genetic Tests for Hyperpituitarism

Sources

Anatomical Context for Hyperpituitarism

MalaCards organs/tissues related to Hyperpituitarism:

⁴²

Pituitary, Bone, Brain, Liver, Testes, Skeletal Muscle, Heart

Sources

Publications for Hyperpituitarism

Articles related to Hyperpituitarism:

#	Title	Authors	Year
1	Hyperpituitarism ( 29489207 )	Gounden V....Jialal I.	2018
2	Congenital hyperpituitarism of hypothalamic origin: a new diencephalic syndrome with endocrine manifestations. ( 14444640 )	Seip M.	1959
3	Psychological findings in a case of von Recklinghausen's disease and hyperpituitarism. ( 13367234 )	JORDAN T.E.	1956
4	Further evidence that hyperthyroidism (Graves' disease) is not hyperpituitarism: effects of triiodothyronine and sodium iodide. ( 14367487 )	WERNER S.C....Hamilton H.	1955
5	Graves' disease: hyperthyroidism or hyperpituitarism. ( 13022743 )	WERNER S.C....Nemeth M.	1952
6	Creatine-creatinine metabolism in adult and juvenile hyperpituitarism. ( 18877070 )	SCHRIRE I.	1948
7	Hyperpituitarism and Hypopituitarism. ( 19312151 )	DAVIDOFF L.M.	1940
8	Thyrotoxicosis with Unilateral Exophthalmos, Hyperpituitarism, and Infantile Hemiplegia. ( 19990197 )	Worster-Drought C.	1935
9	Case of Hyperpituitarism. ( 19984234 )		1925

Sources

Genes for Hyperpituitarism

Genes related to Hyperpituitarism (0 elite genes):

(show all 11)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	IGF1	Insulin Like Growth Factor 1	Protein Coding	20.06	DISEASES inferred ¹⁵
2	SST	Somatostatin	Protein Coding	19.62	DISEASES inferred ¹⁵
3	GHRH	Growth Hormone Releasing Hormone	Protein Coding	18.31	DISEASES inferred ¹⁵
4	PRL	Prolactin	Protein Coding	17.93	DISEASES inferred ¹⁵
5	TRH	Thyrotropin Releasing Hormone	Protein Coding	17.78	DISEASES inferred ¹⁵
6	POMC	Proopiomelanocortin	Protein Coding	17.49	DISEASES inferred ¹⁵
7	GH1	Growth Hormone 1	Protein Coding	17.32	DISEASES inferred ¹⁵
8	GHR	Growth Hormone Receptor	Protein Coding	17.31	DISEASES inferred ¹⁵
9	AIP	Aryl Hydrocarbon Receptor Interacting Protein	Protein Coding	17.3	DISEASES inferred ¹⁵
10	SSTR2	Somatostatin Receptor 2	Protein Coding	17.04	DISEASES inferred ¹⁵
11	INS	Insulin	Protein Coding	17.04	DISEASES inferred ¹⁵

Sources

Variations for Hyperpituitarism

Sources

Expression for Hyperpituitarism

Search GEO for disease gene expression data for Hyperpituitarism.

Sources

Pathways for Hyperpituitarism

Pathways related to Hyperpituitarism according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	TGF-Beta Pathway ⁶⁵ Show member pathways JAK-STAT Pathway ⁶⁵ JNK Pathway ⁶⁵ MAPK Family Pathway ⁶⁵ Regulation of eIF4 and p70S6K ⁶⁵ SOCS Pathway ⁶⁵	13.12	GH1 GHR GHRH IGF1 INS PRL
2	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	12.55	GH1 GHR IGF1 INS PRL
3	Regulation of lipid metabolism Insulin signaling-generic cascades ²³ Show member pathways acetyl-CoA biosynthesis from citrate ¹ Butyrate-induced histone acetylation ¹ Cell adhesion PLAU signaling ²³ Class IB PI3K non-lipid kinase events ¹ Development CNTF receptor signaling ²³ Development Growth hormone signaling via PI3K/AKT and MAPK cascades ²³ ErbB2/ErbB3 signaling events ¹ Glucose Homeostasis ¹ Insulin signaling pathway ³⁸ IRS activation ⁶⁷ Signal attenuation ⁶⁷ Transcription Receptor-mediated HIF regulation ²³ Translation Regulation of EIF2 activity ²³ Translation Regulation of EIF4F activity ²³ Translation Insulin regulation of translation ²³	12.53	GH1 GHR IGF1 INS
4	Peptide ligand-binding receptors ⁶⁷ Show member pathways Class A/1 (Rhodopsin-like receptors) ⁶⁷ Defective AVP causes neurohypophyseal diabetes insipidus (NDI) ⁶⁷ Formyl peptide receptors bind formyl peptides and many other ligands ⁶⁷ G alpha (i) signalling events ⁶⁷ GPCR ligand binding ⁶⁷ GPCRs, Class A Rhodopsin-like ¹ Neuroactive ligand-receptor interaction ³⁸ Orexin and neuropeptides FF and QRFP bind to their respective receptors ⁶⁷ Peptide GPCRs ¹ Tachykinin receptors bind tachykinins ⁶⁷ Vasopressin-like receptors ⁶⁷	12.51	GH1 GHR GHRH POMC PRL SST
5	Peptide hormone metabolism ⁶⁷ Show member pathways Glycoprotein hormones ⁶⁷ Insulin processing ⁶⁷ Metabolism of Angiotensinogen to Angiotensins ⁶⁷ Peptide hormone biosynthesis ⁶⁷ Synthesis, secretion, and deacylation of Ghrelin ⁶⁷	11.72	GH1 IGF1 INS POMC
6	Adipogenesis ¹	11.66	GH1 IGF1 INS
7	Endochondral Ossification ¹	11.25	GH1 GHR IGF1
8	Aldosterone-regulated sodium reabsorption ³⁸	11.05	IGF1 INS
9	Development_Leptin signaling via JAK/STAT and MAPK cascades ²³ Show member pathways phospho-PLA2 pathway ⁶⁷	10.91	POMC TRH
10	Growth hormone receptor signaling ⁶⁷ Show member pathways Prolactin receptor signaling ⁶⁷	10.74	GH1 GHR PRL

Sources

GO Terms for Hyperpituitarism

Cellular components related to Hyperpituitarism according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.76	GH1 GHR GHRH IGF1 INS POMC
2	secretory granule	GO:0030141	9.32	POMC TRH
3	extracellular region	GO:0005576	9.28	GH1 GHR GHRH IGF1 INS POMC
4	growth hormone receptor complex	GO:0070195	9.26	GH1 GHR
5	endosome lumen	GO:0031904	9.13	GH1 INS PRL

Biological processes related to Hyperpituitarism according to GeneCards Suite gene sharing:

(show all 23)

#	Name	GO ID	Score	Top Affiliating Genes
1	G protein-coupled receptor signaling pathway	GO:0007186	9.95	GHRH INS POMC SST SSTR2 TRH
2	positive regulation of cell proliferation	GO:0008284	9.89	GHRH IGF1 INS PRL
3	cellular protein metabolic process	GO:0044267	9.79	IGF1 INS PRL
4	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	9.7	GH1 GHR IGF1
5	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.67	GH1 IGF1 INS
6	cell-cell signaling	GO:0007267	9.65	GHRH INS POMC SST TRH
7	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.63	GH1 GHR IGF1
8	activation of protein kinase B activity	GO:0032148	9.61	IGF1 INS
9	positive regulation of glucose import	GO:0046326	9.6	IGF1 INS
10	positive regulation of mitotic nuclear division	GO:0045840	9.58	IGF1 INS
11	response to food	GO:0032094	9.58	GHR GHRH
12	positive regulation of multicellular organism growth	GO:0040018	9.58	GH1 GHR GHRH
13	positive regulation of glycolytic process	GO:0045821	9.57	IGF1 INS
14	positive regulation of glycogen biosynthetic process	GO:0045725	9.56	IGF1 INS
15	insulin-like growth factor receptor signaling pathway	GO:0048009	9.55	GHR IGF1
16	growth hormone receptor signaling pathway	GO:0060396	9.54	GH1 GHR
17	regulation of multicellular organism growth	GO:0040014	9.54	GHR IGF1 PRL
18	negative regulation of feeding behavior	GO:2000252	9.51	INS TRH
19	positive regulation of JAK-STAT cascade	GO:0046427	9.5	GH1 GHR PRL
20	positive regulation of lactation	GO:1903489	9.43	GHRH PRL
21	JAK-STAT cascade involved in growth hormone signaling pathway	GO:0060397	9.33	GH1 GHR PRL
22	regulation of signaling receptor activity	GO:0010469	9.23	GH1 GHRH IGF1 INS POMC PRL
23	positive regulation of insulin-like growth factor receptor signaling pathway	GO:0043568	9.13	GH1 GHRH IGF1

Molecular functions related to Hyperpituitarism according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	insulin receptor binding	GO:0005158	9.26	IGF1 INS
2	hormone activity	GO:0005179	9.23	GH1 GHRH IGF1 INS POMC PRL
3	insulin-like growth factor receptor binding	GO:0005159	9.16	IGF1 INS
4	prolactin receptor binding	GO:0005148	8.96	GH1 PRL

Sources

Sources for Hyperpituitarism

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia